Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
NCT ID: NCT07146022
Last Updated: 2025-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
552 participants
INTERVENTIONAL
2025-07-25
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA.
This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264
Efficacy and Safety of VDPHL01 in Males With AGA
NCT06724614
Safety and Efficacy of VDPHL01 in Males and Females With AGA
NCT06527365
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
NCT03474718
Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
NCT07012486
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VDPHL01 BID
VDPHL01 will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will continue VDPHL01 BID for an additional 6 months.
VDPHL01 BID
VDPHL01 Extended Release (ER) Tablet
VDPHL01 QD and Placebo QD
Placebo will be taken orally once a day (QD) in the AM or PM. VDPHL01 will be taken orally once a day (QD) in the AM or PM for the first 6 months of the study. After month 6, subject will continue this same dose regimen for an additional 6 months.
VDPHL01 QD
VDPHL01 Extended Release (ER) Tablet
Placebo
Placebo tablet
Placebo BID with treatment extension to VDPHL01 BID
Placebo will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will switch to VDPHL01 BID group, and take VDPHL01 orally twice a day (BID), once in the AM and once in the PM for an additional 6 months.
Placebo
Placebo tablet
Placebo
Placebo tablet
Placebo BID with treatment extension to VDPHL01 QD and Placebo QD
Placebo will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will switch to VDPHL01 QD and Placebo QD group, and take placebo orally once a day in the AM or PM; VDPHL01 will be taken orally once a day in the AM or PM for an additional 6 months.
Placebo
Placebo tablet
Placebo
Placebo tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VDPHL01 QD
VDPHL01 Extended Release (ER) Tablet
Placebo
Placebo tablet
VDPHL01 BID
VDPHL01 Extended Release (ER) Tablet
Placebo
Placebo tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a clinical diagnosis of mild to moderate AGA;
* Subject is in good general health and has adequate renal and hepatic function;
* Subject is willing to maintain at least 1/4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study;
* Subject is willing and able to administer the test article as directed and can read, understand, and complete the required questionnaires in English;
* Subject is willing and able to swallow study drug whole;
* Subject agrees to have a micro dot tattoo placed on their scalp;
* Subject agrees to have this area photographed at study visits as indicated in the protocol.
Exclusion Criteria
* Subject has symptoms or history of certain heart or thyroid conditions;
* Subject has a history of or active hair loss due to conditions/diseases other than AGA;
* Subject has a current or recent history of dietary or weight changes, including use of GLP-1 agonists;
* Subject has been diagnosed with COVID-19 within 16 weeks of baseline;
* Subject has had previous radiation of the scalp;
* Use of any of the following treatments within the indicated washout period before screening:
* Subject has used hormone replacement therapy or hormonal modulators within 6 months prior to screening
* Subject has used oral treatments for hair growth or that can affect hair growth, including systemic retinoids, within 6 months of screening
* Subject has used systemic calcium channel blockers or beta blockers within 12 weeks prior to screening
* Subject has used systemic cimetidine, ketoconazole, diazoxide, or corticosteroids (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening
* Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, injections, platelet rich plasma within 6 months prior to screening
* Subject has used any topical scalp treatments for hair growth within 12 weeks prior to screening
* Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study;
* Subject has any other condition that, in the investigator's opinion, interfere with the study
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Veradermics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Reid Waldman, M.D.
Role: STUDY_CHAIR
Veradermics, Inc.
Timothy Durso, M.D.
Role: STUDY_CHAIR
Veradermics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 73
Birmingham, Alabama, United States
Site 89
Birmingham, Alabama, United States
Site 77
Phoenix, Arizona, United States
Site 30
Fort Smith, Arkansas, United States
Site 69
Encino, California, United States
Site 2
Fremont, California, United States
Site 64
Manhattan Beach, California, United States
Site 93
Northridge, California, United States
Site 66
Santa Monica, California, United States
Site 34
Sherman Oaks, California, United States
Site 94
Thousand Oaks, California, United States
Site 21
Vista, California, United States
Site 5
Castle Rock, Colorado, United States
Site 24
Greenwood Village, Colorado, United States
Site 17
Aventura, Florida, United States
Site 71
Boca Raton, Florida, United States
Site 86
Coral Gables, Florida, United States
Site 62
Coral Gables, Florida, United States
Site 99
Miami, Florida, United States
Site 54
Ocala, Florida, United States
Site 43
Atlanta, Georgia, United States
Site 90
Sandy Springs, Georgia, United States
Site 31
Boise, Idaho, United States
Site 61
Chicago, Illinois, United States
Site 53
Clarksville, Indiana, United States
Site 15
Indianapolis, Indiana, United States
Site 32
New Albany, Indiana, United States
Site 55
Plainfield, Indiana, United States
Site 27
West Lafayette, Indiana, United States
Site 79
Leawood, Kansas, United States
Site 52
Louisville, Kentucky, United States
Site 41
Baton Rouge, Louisiana, United States
Site 13
Covington, Louisiana, United States
Site 12
Metairie, Louisiana, United States
Site 75
New Orleans, Louisiana, United States
Site 84
Glenn Dale, Maryland, United States
Site 87
Rockville, Maryland, United States
Site 22
Brighton, Massachusetts, United States
Site 80
Chestnut Hill, Massachusetts, United States
Site 59
Quincy, Massachusetts, United States
Site 26
Clarkston, Michigan, United States
Site 68
Clinton Township, Michigan, United States
Site 83
Southfield, Michigan, United States
Site 98
Medina, Minnesota, United States
Site 56
Minneapolis, Minnesota, United States
Site 6
New Brighton, Minnesota, United States
Site 18
Hackensack, New Jersey, United States
Site 37
Kew Gardens, New York, United States
Site 97
New York, New York, United States
Site 82
Hickory, North Carolina, United States
Site 92
Huntersville, North Carolina, United States
Site 39
Boardman, Ohio, United States
Site 72
Cincinnati, Ohio, United States
Site 11
Columbus, Ohio, United States
Site 57
Portland, Oregon, United States
Site 60
Anderson, South Carolina, United States
Site 95
Hermitage, Tennessee, United States
Site 9
Knoxville, Tennessee, United States
Site 4
Nashville, Tennessee, United States
Site 76
Austin, Texas, United States
Site 74
College Station, Texas, United States
Site 67
Dallas, Texas, United States
Site 14
Houston, Texas, United States
Site 88
San Antonio, Texas, United States
Site 91
Sugar Land, Texas, United States
Site 19
South Jordan, Utah, United States
Site 29
Forest, Virginia, United States
Site 63
Norfolk, Virginia, United States
Site 85
Norfolk, Virginia, United States
Site 33
Burien, Washington, United States
Site 70
Mill Creek, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
250-13951-306
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.